Cowen Group Inc. purchased a new stake in Cytosorbents Corporation (NASDAQ:CTSO) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 55,065 shares of the medical research company’s stock, valued at approximately $248,000. Cowen Group Inc. owned approximately 0.22% of Cytosorbents Corporation at the end of the most recent quarter.
Separately, Segantii Capital Management Ltd increased its stake in shares of Cytosorbents Corporation by 563.4% in the first quarter. Segantii Capital Management Ltd now owns 27,200 shares of the medical research company’s stock valued at $122,000 after buying an additional 23,100 shares during the period. Institutional investors and hedge funds own 8.75% of the company’s stock.
Cytosorbents Corporation (NASDAQ:CTSO) traded up 6.67% during mid-day trading on Tuesday, reaching $4.00. The company’s stock had a trading volume of 52,985 shares. Cytosorbents Corporation has a 12-month low of $3.30 and a 12-month high of $6.90. The firm’s market cap is $112.43 million. The company has a 50-day moving average price of $4.24 and a 200-day moving average price of $5.07.
Cytosorbents Corporation (NASDAQ:CTSO) last posted its earnings results on Monday, May 8th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.06. The company had revenue of $3.11 million during the quarter, compared to the consensus estimate of $2.99 million. Cytosorbents Corporation had a negative net margin of 108.69% and a negative return on equity of 1,426.21%. On average, equities research analysts expect that Cytosorbents Corporation will post ($0.28) earnings per share for the current year.
A number of brokerages recently commented on CTSO. B. Riley reaffirmed a “buy” rating and set a $11.25 price target on shares of Cytosorbents Corporation in a research report on Tuesday, April 11th. Maxim Group set a $10.00 price target on Cytosorbents Corporation and gave the company a “buy” rating in a research report on Saturday, May 6th. Cowen and Company began coverage on Cytosorbents Corporation in a research report on Wednesday, June 7th. They set an “outperform” rating and a $7.00 price target for the company. Finally, Aegis reaffirmed a “buy” rating on shares of Cytosorbents Corporation in a research report on Tuesday, March 7th. Six equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average target price of $12.38.
In other Cytosorbents Corporation news, insider Phillip P. Chan bought 6,300 shares of the firm’s stock in a transaction that occurred on Monday, June 5th. The stock was bought at an average cost of $4.00 per share, for a total transaction of $25,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have purchased 17,500 shares of company stock valued at $70,620 over the last 90 days. 5.60% of the stock is currently owned by insiders.
Cytosorbents Corporation Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with MarketBeat.com's FREE daily email newsletter.